TDO2 and neoplasm: BzATP increased the uptake of TO-PRO-3 in immune cells from both non-tumor and tumor areas (Figure 2A-B). This increase was prevented in cells pre-treated with the specific P2RX7 inhibitor, GSK1370319A 35, indicating that TO-PRO-3 uptake was dependent on the expression of P2RX7.